Medication info
Exban Tablet 40mg (Valsartan)

Exban Tablet 40mg (Valsartan)

Prescription medicationTabletOral
Ingredient · strength
Valsartan›80mg / 1 tablet
Manufacturer / importer
Sanjin Pharmaceutical Co., Ltd.
Appearance
Yellow oval film-coated tablet
Packaging
30 tablets/bottle
Approval status
Active

MFDS item code 202502531 · Approved 2025.09.24 · Insurance code 647805970

Summary

Main use
Treatment of essential hypertension, reduction of the risk of death after myocardial infarction, and treatment of heart failure
Who takes it
Adults · Children
Adult dose
* 40, 80, 160 mg 1. Essential hypertension Take with water during or between meals. It is recommended that the medicine be taken at the same time each day, if possible (e.g., in the morning). 1) Adults: The recommended dose is valsartan 80 mg orally once daily, regardless of sex or race. The blood-pressure-lowering effect develops gradually within 2 weeks and reaches its maximum after 4 weeks. For patients whose blood pressure is not adequately controlled, the dose may be increased to 160 mg once daily or a diuretic may be given concomitantly. If further blood pressure reduction is needed, the dose may be increased to a maximum of 320 mg daily. 2) Older adults (75 years and older): Start treatment with 40 mg once daily. 3) Patients with renal impairment: (1) Creatinine clearance 20 ∼ 50 mL/min: No dosage adjustment is necessary. (2) Creatinine clearance 10 ∼ 20 mL/min: Start treatment with 40 mg once daily. (3) Creatinine clearance less than 10 mL/min and patients on dialysis: Do not administer this medicine. 4) Patients with intravascular volume depletion: For patients with intravascular volume depletion (e.g., patients taking high doses of diuretics whose dose cannot be reduced), start treatment with 40 mg once daily. 5) Patients with hepatic impairment: In patients with mild to moderate hepatic impairment, start treatment with 40 mg once daily; the dose must not exceed 80 mg daily. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis. 2. Heart failure Adults: The recommended initial dose is 40 mg orally twice daily. The dose may be increased to 80 mg or 160 mg per dose. When administered concomitantly with a diuretic, a reduction in the diuretic dose should be considered. The maximum daily dose is 320 mg, given in divided doses. Triple therapy with this medicine, an ACE inhibitor, and a beta-blocker is not recommended. 3. Reduction of the risk of death after myocardial infarction Adults: Treatment may be started within 12 hours after the onset of myocardial infarction. The recommended initial dose is 20 mg twice daily. The dose is then increased over several weeks, taking the patient's tolerability into account, to 40 mg, 80 mg, and 160 mg per dose twice daily. Consider dose reduction if symptoms of hypotension or renal failure occur. This medicine may also be administered to patients receiving other treatments after myocardial infarction (e.g., thrombolytic agents, acetylsalicylic acid, beta-blockers, and statins). However, concomitant use with an ACE inhibitor is not recommended. 4. Patients with renal impairment: No dosage adjustment is necessary if creatinine clearance is 10 mL/min or greater. However, because there is no experience with use in patients with creatinine clearance less than 10 mL/min or in patients on dialysis, do not administer this medicine to these patients. 5. Patients with hepatic impairment: In patients with mild to moderate hepatic impairment, the daily dose of this medicine should preferably not exceed 80 mg. If a dose of 80 mg or more daily is administered, consider whether the benefits of treatment outweigh the risks when increasing the dose. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis.
Child dose
Safety and efficacy have not been established in children and adolescents under 18 years of age. Safety and efficacy have not been established in children and adolescents under 18 years of age.

Ingredients

Manufacturer
Sanjin Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of essential hypertension, reduction of the risk of death after myocardial infarction, and treatment of heart failure

  • Essential hypertension
  • heart failure
  • left ventricular failure
  • left ventricular dysfunction
View approved original text

This medication helps control essential hypertension and is suitable for heart failure patients who cannot use ACE inhibitors. It is also used to reduce the risk of death in patients with left ventricular failure or dysfunction following a myocardial infarction. In other words, it is effective for managing hypertension, treating certain heart failures, and reducing risk after a myocardial infarction. This efficacy can help improve the patient's heart health.

How to take

Adult dose

* 40, 80, 160 mg 1. Essential hypertension Take with water during or between meals. It is recommended that the medicine be taken at the same time each day, if possible (e.g., in the morning). 1) Adults: The recommended dose is valsartan 80 mg orally once daily, regardless of sex or race. The blood-pressure-lowering effect develops gradually within 2 weeks and reaches its maximum after 4 weeks. For patients whose blood pressure is not adequately controlled, the dose may be increased to 160 mg once daily or a diuretic may be given concomitantly. If further blood pressure reduction is needed, the dose may be increased to a maximum of 320 mg daily. 2) Older adults (75 years and older): Start treatment with 40 mg once daily. 3) Patients with renal impairment: (1) Creatinine clearance 20 ∼ 50 mL/min: No dosage adjustment is necessary. (2) Creatinine clearance 10 ∼ 20 mL/min: Start treatment with 40 mg once daily. (3) Creatinine clearance less than 10 mL/min and patients on dialysis: Do not administer this medicine. 4) Patients with intravascular volume depletion: For patients with intravascular volume depletion (e.g., patients taking high doses of diuretics whose dose cannot be reduced), start treatment with 40 mg once daily. 5) Patients with hepatic impairment: In patients with mild to moderate hepatic impairment, start treatment with 40 mg once daily; the dose must not exceed 80 mg daily. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis. 2. Heart failure Adults: The recommended initial dose is 40 mg orally twice daily. The dose may be increased to 80 mg or 160 mg per dose. When administered concomitantly with a diuretic, a reduction in the diuretic dose should be considered. The maximum daily dose is 320 mg, given in divided doses. Triple therapy with this medicine, an ACE inhibitor, and a beta-blocker is not recommended. 3. Reduction of the risk of death after myocardial infarction Adults: Treatment may be started within 12 hours after the onset of myocardial infarction. The recommended initial dose is 20 mg twice daily. The dose is then increased over several weeks, taking the patient's tolerability into account, to 40 mg, 80 mg, and 160 mg per dose twice daily. Consider dose reduction if symptoms of hypotension or renal failure occur. This medicine may also be administered to patients receiving other treatments after myocardial infarction (e.g., thrombolytic agents, acetylsalicylic acid, beta-blockers, and statins). However, concomitant use with an ACE inhibitor is not recommended. 4. Patients with renal impairment: No dosage adjustment is necessary if creatinine clearance is 10 mL/min or greater. However, because there is no experience with use in patients with creatinine clearance less than 10 mL/min or in patients on dialysis, do not administer this medicine to these patients. 5. Patients with hepatic impairment: In patients with mild to moderate hepatic impairment, the daily dose of this medicine should preferably not exceed 80 mg. If a dose of 80 mg or more daily is administered, consider whether the benefits of treatment outweigh the risks when increasing the dose. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis.

Child dose

Safety and efficacy have not been established in children and adolescents under 18 years of age. Safety and efficacy have not been established in children and adolescents under 18 years of age.

Precautions

This medication can cause serious harm to the fetus if taken during pregnancy, especially during the second and third trimesters, so it should be discontinued immediately upon confirmation of pregnancy. This medication should not be used in patients with certain conditions, such as those with very poor liver or kidney function, pregnant or breastfeeding women, and patients who are allergic to this drug or its components. Elderly patients, patients with hyperkalemia, and those with weakened liver function should be monitored more closely when using this medication. Side effects may include headache, dizziness, cough, diarrhea, and fatigue, among others, and serious side effects such as angioedema or renal dysfunction can occur rarely. In particular, patients with heart failure or myocardial infarction should carefully monitor changes in kidney function and blood pressure while taking this medication. This medication may interact with other antihypertensives, diuretics, or potassium-sparing medications, so it is essential to consult a doctor or pharmacist about any other medications being taken. Women who are pregnant or planning to become pregnant should not take this medication, and breastfeeding women should also avoid its use. This medication is not recommended for use in children or adolescents under 18, as safety and efficacy have not been established. In the case of overdose, severe hypotension or shock symptoms may occur, requiring immediate medical attention, and it should be kept out of reach of children. During treatment with this medication, regular checks of blood pressure, kidney function, and serum potassium levels are essential, and any unusual symptoms should be reported to healthcare professionals immediately.

Side effects

  • Headache
  • dizziness
  • viral infection
  • upper respiratory tract infection
  • cough
  • diarrhea
  • fatigue
  • rhinitis
  • sinusitis
  • abdominal pain
Show 37 more
  • stomachache
  • nausea
  • pharyngitis
  • joint pain
  • hypotension
  • orthostatic dizziness
  • orthostatic hypotension
  • renal function impairment
  • hyperkalemia
  • angioedema
  • arrhythmia
  • drowsiness
  • atrial fibrillation
  • vomiting
  • constipation
  • dry mouth
  • loss of appetite
  • malaise
  • vascular edema
  • erythema
  • itching
  • serum sickness
  • vasculitis
  • syncope
  • epistaxis
  • hepatitis
  • interstitial pneumonia
  • hypoglycemia
  • shock
  • loss of consciousness
  • rhabdomyolysis
  • agranulocytosis
  • leukopenia
  • thrombocytopenia
  • vesicular dermatitis
  • decrease in red blood cell volume
  • decrease in hemoglobin

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to prevent air and moisture from entering. Additionally, it is important to store it in a cool place below 30 degrees Celsius to maintain the drug's effectiveness.

Appearance and packaging

Appearance

Yellow oval film-coated tablet

Package unit

30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.